📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick

Published 02/15/2024, 03:43 PM
Updated 02/15/2024, 03:47 PM
© Reuters.  Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
VRTX
-
INSM
-
RAPT
-
IMVT
-

Wolfe Research has initiated coverage on the biotechnology sector, selecting 13 companies with a thematic focus on immunology and genetic medicines.

Six of those stocks have been rated Peer Perform by analysts at Wolfe, including Alpine Immune Sciences (NASDAQ:ALPN), which is also their Top Pick.

“ALPN will have a catalyst-rich 2024, where we expect favorable readouts on IgA nephropathy (IgAN) in H1 and H2 and positive readthrough from Vera’s Wk96 data in Q4,” the analysts wrote in the note.

“Our conviction comes from the de-risked BAFF/APRIL mechanism, with Vera’s Wk72 data validating its efficacy across multiple endpoints. Compared to competitors, povetacicpet has a superior clinical profile with dosing convenience, and we are bullish heading into the clinical readouts in 2024.”

Furthermore, the anticipated HELIOS-B clinical results, are expected around March/April 2024.

HELIOS-B is a study assessing investigational vutrisiran for treating cardiomyopathy in ATTR amyloidosis patients. The developments of this trial will be closely monitored by investors.

“We are optimistic about HELIOS-B’s success, but a failure could be catastrophic for ALNY. A trial success does not spell disproportionate upside for ALNY either, because much of the revenue may already be priced in, and we foresee a competitive cardiomyopathy market,” the analysts said.

In addition to Alpine, six more stocks were initiated at Outperform at Wolfe, including Immunovant, Inc. (NASDAQ:IMVT), Insmed Incorporated (NASDAQ:INSM), Molecular Templates, Inc. (MLTX), I, Roivant Sciences Ltd. (NASDAQ:ROIV), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), and RAPT Therapeutics, Inc. (NASDAQ:RAPT).

On the other hand, Alnylam Pharmaceuticals (ALNY), argenx SE (ARGX), CRISPR Therapeutics AG (CRSP), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Kymera Therapeutics, Inc. (KYMR), and Intellia Therapeutics, Inc. (NASDAQ:NTLA) were rated Peer Perform.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.